TCWA
TEVA icon

Ten Capital Wealth Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Ten Capital Wealth Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-66
Closed -$584 – 499
2023
Q1 		$584 Hold
66
– – ﹤0.01% 500
2022
Q4 		$602 Hold
66
– – ﹤0.01% 523
2022
Q3 		$1K Hold
66
– – ﹤0.01% 536
2022
Q2 		$0 Hold
66
– – ﹤0.01% 521
2022
Q1 		$1K Hold
66
– – ﹤0.01% 462
2021
Q4 		$1K Sell
66
-109
-62% -$984 ﹤0.01% 460
2021
Q3 		$2K Hold
175
– – ﹤0.01% 371
2021
Q2 		$2K Buy
175
+66
+61% +$699 ﹤0.01% 424
2021
Q1 		$1K Hold
109
– – ﹤0.01% 344
2020
Q4 		$1K Buy
+109
New +$1.04K ﹤0.01% 355

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ten Capital Wealth Advisors's TEVA Position: Q2 2023 in Review

Ten Capital Wealth Advisors sold out of Teva Pharmaceuticals (TEVA) in Q2 2023, closing a stake of 66 shares — an estimated $584 sold.

Ten Capital Wealth Advisors first reported a position in TEVA in Q4 2020 and held it in 10 quarters. The position peaked at $2K in Q3 2021. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

  • Ten Capital Wealth Advisors reported no remaining Teva Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Ten Capital Wealth Advisors sold 66 Teva Pharmaceuticals shares in Q2 2023, an estimated $584.
  • Ten Capital Wealth Advisors first reported a position in Teva Pharmaceuticals in Q4 2020 and held it in 10 quarters.
  • Ten Capital Wealth Advisors's Teva Pharmaceuticals position peaked at $2K in Q3 2021.
  • 428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on Ten Capital Wealth Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.